The goal of this study was to clarify that blockade of adenosine receptors during myocardial ischemia causes further reductions in coronary blood flow due to platelet aggregation. Coronary perfusion pressure in 47 open-chest dogs was reduced such that coronary blood flow decreased to one fifth of the control value; thereafter, coronary perfusion pressure was maintained at the low levels. During hypoperfusion, coronary flow was kept low but constant with a massive release of adenosine. When 8-phenyltheophylline, an adenosine receptor antagonist, was infused during coronary hypoperfusion, coronary blood flow (18±t 2 ml/100 g/min) gradually decreased at 5-10 minutes of ischemia and reached almost zero at 20 minutes. Three minutes after the onset of ischemia, before further reduction of coronary flow, the microscopic examination revealed the existence of thromboembolization in the small coronary arteries, and the number of platelets in the regional coronary venous blood were significantly decreased, indicating that a further reduction of coronary flow due to treatment with 8-phenyltheophylline is attributed to thromboembolism caused by platelet aggregations. This reduction of coronary flow and formation of thromboembolism were inhibited by the treatments with dibutyryl cAMP, forskolin, and yohimbine, indicating that this thromboembolization during a lack of adenosine activity is due to platelet aggregation and that platelet aggregation caused by 8-phenyltheophylline is triggered by stimulation of a2-adrenoceptors by released norepinephrine during ischemia. We demonstrate that adenosine, generated endogenously in response to ischemia, inhibits platelet aggregation. The has been no report that endogenous adenosine during myocardial ischemia benefits inhibition of thromboembolization due to platelet aggregation in coronary small arteries. We report here evidence that, during ischemia, released adenosine potentially inhibits thromboembolism that is primarily due to platelet aggregation. This novel and fundamental phenomenon preserves normal functional capacities of coronary circulation during and after ischemia.
inhibitor of platelet aggregation through A2-adenosine receptors of the platelets.4-8 However, until now, there has been no report that endogenous adenosine during myocardial ischemia benefits inhibition of thromboembolization due to platelet aggregation in coronary small arteries. We report here evidence that, during ischemia, released adenosine potentially inhibits thromboembolism that is primarily due to platelet aggregation. This novel and fundamental phenomenon preserves normal functional capacities of coronary circulation during and after ischemia.
Materials and Methods Instrumentation
Forty-seven mongrel dogs weighing 16-22 kg were anesthetized with pentobarbital sodium (30 mg/kg). The trachea was intubated, and the dog was ventilated with room air with oxygen. The chest was opened through the left fifth intercostal space, and the heart was suspended in a pericardial cradle. We cannulated and perfused the left anterior descending coronary artery with blood via the carotid artery through an extracorporeal bypass tube after heparinization (500 units/kg). Coronary blood flow (CBF) was measured with an electromagnetic flow probe attached at the bypass tube, and coronary perfusion pressure (CPP) was monitored at the tip of the coronary arterial cannula. A small, short collecting tube was cannulated into a small coronary vein near the center of the perfused area to sample coronary venous blood. The drained venous blood was collected in a reservoir placed at the level of the left atrium. A high fidelity of left ventricular pressure and its first derivative were measured by a micromanometer (model P-5, Konigsberg Instruments, Inc., Pasadena, Calif.) placed in the left ventricular cavity through the apex. A pair of ultrasonic crystals was placed in the center of the perfused area -1 cm apart to measure myocardial segment length with an ultrasonic dimension gauge (5 and forskolin (0.3 ,ug/kg/min i.c., n=5). This is because both db-cAMP and forskolin are reported to inhibit platelet aggregation.4-8 Moreover, to investigate the triggering mechanisms of the platelet aggregation due to adenosine receptor antagonization, propranolol (10 ,ug/kg/min, n=5), prazosin (4 ,g/kg/min i.c., n =5), and yohimbine (4 ,ug/kg/min i.c., n =5) were administered in the ischemic hearts under the treatment with 8-phenyltheophylline.
Chemical Analysis Lactate measurements. Lactate was assessed by enzymatic assay,9,'0 and the lactate extraction ratio was obtained by coronary arteriovenous difference in lactate concentration multiplied by 100 and divided by arterial lactate concentration.
Adenosine measurements. The method of adenosine measurements has been reported previously.9-'3 One milliliter of blood was drawn into a syringe containing 0.5 ml of 0.03% dipyridamole and 0.1 ml of 160 mM MnCl2 to make the final concentration of each chemical 0.01% and 10 mM, respectively. Dipyridamole blocked the uptake of adenosine by both red blood cells and platelets, and MnCl2 blocked the degradation of adenosine. Sampled blood was quickly put into iced water to prevent release of adenosine from red blood cells. After centrifugation, the supernatant was obtained, and radioimmunoassay methods were used for analyzing the adenosine content. Briefly, adenosine in the plasma (100 ,l) was succinylated by 100 ,ul dioxane containing succinic acid anhydride and triethylamine. After a 10-minute incubation, the mixture was diluted with 800 ,ul of 0.3 M imidazole buffer (pH 6.5). The assay mixture contained 100 gl sample, 100 ,l succinyl [3Hladeno-sine (25,000 counts/min in an amount of 1 pmol), and 100 /l diluted anti-adenosine serum. After the mixture was kept in an ice-cold water bath for 24 hours, a cool suspension of dextran-coated charcoal (500 ,ul) was added. The charcoal was spun down, and 0.5 ml supernatant was counted for radioactivity in a liquid scintillation counter. The amount of adenosine degradation during the sampling procedure and degradation rate of adenosine were negligible.9"11
Norepinephrine measurements. The method of norepinephrine measurements has been described previously.14 Five milliliters of coronary arterial and venous blood taken into a tube containing EDTA was immediately placed in iced water and centrifuged for 20 minutes. Plasma norepinephrine was adsorbed on alumina and separated by high-performance liquid chromatography (LC-3A pump, Zpax-SCX column, Shimazu Seisakusho Co.). Plasma norepinephrine was determined spectrofluorometrically by the trihydroxyindole method (RF-500LCA spectrofluorophotometer, Shimazu).
Morphological Studies
After completion of measurements of hemodynamic parameters and blood sampling, heart tissues were prepared for the light microscopic analysis to examine the changes in small coronary arteries as well as in the myocardium.
Statistical Analysis
Statistical analysis was performed with unpaired t test. Multiple analysis of variance was also used to assess the differences of time-response curve between each group. All values were expressed as mean+SEM, and p<0.05 was considered significant. Results In the nonischemic control condition, CPP and CBF were 113+±8 mm Hg and 89±2 ml/100 g/min, respectively. Intracoronary administrations of 8-phenyltheophylline, forskolin, db-cAMP, propranolol, prazosin, and yohimbine changed neither CBF, lactate extraction ratio, nor fractional shortening in the nonischemic condition. Figure 1 shows the changes in CPP and CBF after the reduction of CPP. Without any treatment (open circles in Figure 1, n=5) , both CPP and CBF were maintained unchanged in the low levels. Coronary arteriovenous differences of adenosine were signifi-enhanced to 876±+32 pmol/ml in the 8- condition. In striking contrast, the 8-phenyltheophylg pressure was not changed throughout. Because adenoline-treated hearts exhibited widespread plugging of ?ceptors of the coronary arteries are blocked by 8-phethe small coronary vessels, implying that treatment ophylline (8PT), coronary perfusion pressure, which with 8-phenyl-theophylline during ischemia causes ained onefifth ofthe coronary flow, was higher than that thromboembolism in small coronary vessels. untreated condition. Although coronary perfusion presTo test the idea that the reduction of CBF caused vas kept constant in each group, coronary blood flow by 8-phenyltheophylline during ischemia is related to illy decreased toward zero at 20 minutes after ischeinia the activation of platelets, we examined the effects of 8PT-treated condition. In the untreated condition, db-cAMP and forskolin on this flow reduction. Ad- coronary venous blood were not decreased signifi-.1g. This value is higher (p<O.OO1) than that in cantly. This selective reduction of the number of ntreated condition, indicating that the coronary platelets before the decreases in CBF strongly argues lilatory effects of adenosine are attenuated by against the hypothesis that the stagnant bloodstream mnyltheophylline (solid circles in Figure 1, n=5 It is intriguing to consider the role of adenosine in the neurotransmitter functions of the presynaptic nerve endings. The released adenosine inhibits norepinephrine release18 and attenuates both catecholamine and ischemic injuries. The earlier13 and present studies agree well. However, once this negative feedback mechanism is disordered by blockade of adenosine receptor activities, norepinephrine is continuously released and a2-adrenergic receptors are further stimulated. Indeed, the present study provides supportive evidence that adenosine receptor blockade by 8-phenyltheophylline enhances the release of norepinephrine during ischemia, which further enhances platelet aggregation in the small coronary vessels and worsens myocardial ischemia. Adenosine is revealed to be an important element in this crucial feedback mechanism.
In the clinical settings, thromboembolism in the small coronary arteries can be observed in acute myocardial infarction.19 When myocardial ischemia is prolonged, the capability of adenosine production may be weakened, and adenosine receptors may be desensitized, both attenuating the stimulatory effects of adenosine receptor in platelets. In contrast, release of norepinephrine is closely related to the duration and extent of ischemia17; prolonged ischemia facilitates release of norepinephrine, which further stimulates a2-adrenoceptors in platelets. This unbalance that decreases cAMP concentrations in platelets may cause thromboembolism in coronary small vessels. To prevent the activation of this deleterious vicious cycle, adenosine infusion or potentiation of adenosine production may be promising for the treatment of ischemic heart diseases.
